Harvard Historical Financial Ratios
HBIO Stock | USD 2.20 0.01 0.46% |
Harvard Bioscience is recently reporting on over 112 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 4.65 or Days Sales Outstanding of 73.28 will help investors to properly organize and evaluate Harvard Bioscience financial condition quickly.
Harvard |
About Harvard Financial Ratios Analysis
Harvard BioscienceFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Harvard Bioscience investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Harvard financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Harvard Bioscience history.
Harvard Bioscience Financial Ratios Chart
Add Fundamental
Dividend Yield
Dividend Yield is Harvard Bioscience dividend as a percentage of Harvard Bioscience stock price. Harvard Bioscience dividend yield is a measure of Harvard Bioscience stock productivity, which can be interpreted as interest rate earned on an Harvard Bioscience investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Ev To Operating Cash Flow
A valuation metric comparing the company's enterprise value to its operating cash flow, indicating how many dollars of EV are generated for each dollar of operating cash flows.Most ratios from Harvard Bioscience's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Harvard Bioscience current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.At this time, Harvard Bioscience's Inventory Turnover is very stable compared to the past year. As of the 29th of November 2024, Sales General And Administrative To Revenue is likely to grow to 0.25, while Price To Sales Ratio is likely to drop 1.72.
2023 | 2024 (projected) | Dividend Yield | 0.002551 | 0.002218 | Price To Sales Ratio | 2.02 | 1.72 |
Harvard Bioscience fundamentals Correlations
Click cells to compare fundamentals
Harvard Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Harvard Bioscience fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 0.99 | 1.62 | 2.39 | 1.01 | 2.02 | 1.72 | |
Ptb Ratio | 1.41 | 2.16 | 3.41 | 1.59 | 3.11 | 4.65 | |
Days Sales Outstanding | 65.05 | 63.51 | 67.02 | 53.8 | 52.35 | 73.28 | |
Book Value Per Share | 2.16 | 1.98 | 2.07 | 1.74 | 1.72 | 2.85 | |
Free Cash Flow Yield | 0.0592 | 0.0493 | (2.92E-4) | (0.003818) | 0.0516 | 0.0501 | |
Operating Cash Flow Per Share | 0.0654 | 0.21 | 0.24 | 0.0313 | 0.0278 | 0.33 | |
Stock Based Compensation To Revenue | 0.0261 | 0.0357 | 0.0351 | 0.0389 | 0.0445 | 0.0423 | |
Capex To Depreciation | 0.16 | 0.15 | 0.18 | 0.21 | 0.33 | 0.4 | |
Pb Ratio | 1.41 | 2.16 | 3.41 | 1.59 | 3.11 | 4.65 | |
Free Cash Flow Per Share | 0.18 | 0.21 | (0.002057) | (0.0106) | 0.28 | 0.19 | |
Roic | 0.009254 | (0.005025) | 0.0219 | (0.0624) | 0.0228 | 0.0301 | |
Inventory Turnover | 2.35 | 1.98 | 1.86 | 1.99 | 1.87 | 3.15 | |
Net Income Per Share | (0.12) | (0.2) | (0.007139) | (0.23) | (0.0805) | (0.0845) | |
Days Of Inventory On Hand | 155.29 | 184.43 | 196.47 | 183.76 | 195.36 | 110.58 | |
Payables Turnover | 9.71 | 7.38 | 10.44 | 8.15 | 8.31 | 7.07 | |
Research And Ddevelopement To Revenue | 0.091 | 0.0922 | 0.0851 | 0.0908 | 0.11 | 0.1 | |
Capex To Revenue | 0.008164 | 0.0105 | 0.0113 | 0.014 | 0.0206 | 0.0195 | |
Pocfratio | 14.33 | 17.77 | 225.37 | 99.58 | 16.18 | 15.37 | |
Interest Coverage | 0.27 | (0.12) | 0.91 | (3.19) | 0.53 | 0.55 | |
Capex To Operating Cash Flow | 0.42 | 0.15 | 0.12 | 1.07 | 1.38 | 0.16 | |
Pfcf Ratio | 16.88 | 20.27 | (3.4K) | (261.9) | 19.37 | 20.34 | |
Days Payables Outstanding | 37.58 | 49.47 | 34.97 | 44.81 | 43.9 | 47.73 | |
Income Quality | (1.72) | (1.19) | (4.38) | (0.12) | (4.11) | (3.9) | |
Roe | (0.0574) | (0.1) | (0.003453) | (0.13) | (0.0467) | (0.0491) | |
Ev To Operating Cash Flow | 19.98 | 22.02 | 257.47 | 136.31 | 18.92 | 17.98 | |
Pe Ratio | (24.61) | (21.22) | (987.56) | (12.05) | (66.46) | (63.13) | |
Return On Tangible Assets | (0.0678) | (0.12) | (0.003727) | (0.14) | (0.0531) | (0.0558) | |
Ev To Free Cash Flow | 23.54 | 25.12 | (3.9K) | (358.52) | 22.65 | 23.79 | |
Earnings Yield | (0.0406) | (0.0471) | (0.001013) | (0.083) | (0.015) | (0.0158) | |
Net Debt To E B I T D A | 6.06 | 7.23 | 3.58 | 44.83 | 4.79 | 5.03 | |
Current Ratio | 2.12 | 2.46 | 2.43 | 2.2 | 1.85 | 1.76 | |
Tangible Book Value Per Share | (0.37) | (0.39) | (0.0415) | (0.12) | (6.36E-4) | (6.05E-4) | |
Receivables Turnover | 5.61 | 5.75 | 5.45 | 6.78 | 6.97 | 4.51 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harvard Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Harvard Stock, please use our How to Invest in Harvard Bioscience guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harvard Bioscience. If investors know Harvard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harvard Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.80) | Earnings Share (0.33) | Revenue Per Share 2.258 | Quarterly Revenue Growth (0.13) | Return On Assets (0.02) |
The market value of Harvard Bioscience is measured differently than its book value, which is the value of Harvard that is recorded on the company's balance sheet. Investors also form their own opinion of Harvard Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Harvard Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harvard Bioscience's market value can be influenced by many factors that don't directly affect Harvard Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Harvard Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harvard Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harvard Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.